Antifungal treatment strategies and their impact on resistance development in clinical settings
Journal of Antimicrobial Chemotherapy · 02.12.2025 · 80 (12) · 3208-3226
DOI: 10.1093/jac/dkaf382 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 15.10.2025. Verfasst von Norman Van Rhijn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Manchester Fungal Infection Group, Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine…. Hauptthemen laut MEDLINE: Antifungal Agents, Drug Resistance, Fungal, Invasive Fungal Infections, Fungi. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Invasive fungal diseases, particularly among immunocompromised patients, represent a growing clinical challenge due to limited therapeutic options, diagnostic delays and escalating antifungal resistance. Fungal pathogens employ diverse resistance mechanisms, including genetic mutations of antifungal target enzymes, biofilm formation, efflux pump overexpression and reduced drug penetration, which compromise the efficacy of clinically available antifungal classes. This review explores antifungal treatment modalities and evaluates approaches to mitigate resistance development. Advanced diagnostics and therapeutic drug monitoring are pivotal for enabling timely, targeted therapies and personalizing treatment plans, thus minimizing reliance on broad-spectrum agents. New antifungal agents, such as rezafungin, olorofim and fosmanogepix, along with long-acting and advanced formulations plus combination regimens, show substantial promise for managing resistance and improving treatment outcomes. Additionally, the development of immunotherapies and antifungal vaccines offers new avenues for bolstering host defences against fungal pathogens. Addressing antifungal resistance demands a multifaceted ‘One Health’ approach that integrates robust diagnostics, antifungal stewardship (AFS), precision medicine and collaborative global efforts. By advancing drug formulations, enhancing diagnostic tools and implementing forward-thinking AFS practices, the healthcare community can better tackle the escalating burden of fungal infections and deliver improved patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Manchester Fungal Infection Group, Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
- Public Health Wales (PHW) Mycology Reference Laboratory, University Hospital of Wales, Cardiff, UK.
ORCID-Profile: Norman Van Rhijn, P Lewis White
Zitieren
APA
Van Rhijn, N., & White, P. L. (2025). Antifungal treatment strategies and their impact on resistance development in clinical settings. Journal of Antimicrobial Chemotherapy, 80(12), 3208-3226. https://doi.org/10.1093/jac/dkaf382
Vancouver
Van Rhijn N, White PL. Antifungal treatment strategies and their impact on resistance development in clinical settings. Journal of Antimicrobial Chemotherapy. 2025;80(12):3208-3226. doi:10.1093/jac/dkaf382
BibTeX
@article{VanRhijn2025,
author = {Van Rhijn, Norman and White, P Lewis},
title = {Antifungal treatment strategies and their impact on resistance development in clinical settings},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {12},
pages = {3208--3226},
doi = {10.1093/jac/dkaf382}
}
EUVIMED